Shang Guang-Yao, Zhang Lei, Lin Lin, Jiang Hai-Qiang, Li Chao, Jiang Feng, Qi Dong-Mei, Li Yun-Lun, Yang Wen-Qing
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China.
Faculty of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Evid Based Complement Alternat Med. 2021 Nov 15;2021:4532279. doi: 10.1155/2021/4532279. eCollection 2021.
Traditional Chinese medicine has shown promising results in treating the symptoms of hypertension, a major global health concern not yet fully managed by modern medicine. It is, therefore, of high priority to clarify the altered pathophysiology of hypertension in individuals with liver hyperactivity syndrome (HLYH) in response to effective treatments to better understand this disorder. The primary aim of this study was to construct a personalized syndrome discriminant system based on data capable of informing management strategies prior to the initiation of antihypertensive therapy or the implementation of screening strategies in at-risk HLYH. Based on the successful replication of HLYH rat models, we extracted the core discriminant factors of the disorder through the integration of physical signs, biochemical indicators, and metabolic markers. Macro and micro information was correlated to construct a syndrome discriminant system. At the macroscopic level, HLYH rat models characterized by elevated blood pressure were found to be associated with significant changes in water intake, pain threshold, retention time on a rotating platform, and body surface temperature. A total of 27 potential biomarkers and 14 metabolic pathways appeared to reflect the primary metabolic characteristics. Through the integration of these data, we successfully constructed a combined macro-micro personalized syndrome discriminant system, which provides a foundation for research regarding the risk loci of HLYH. Our findings also broaden our understanding of the biological pathways involved in HLYH.
中医在治疗高血压症状方面已显示出有前景的结果,高血压是一个全球主要的健康问题,现代医学尚未完全解决。因此,为了更好地理解这种疾病,明确肝阳上亢证(HLYH)个体在有效治疗后高血压病理生理学的改变具有高度优先性。本研究的主要目的是基于能够在启动抗高血压治疗或对高危HLYH实施筛查策略之前为管理策略提供信息的数据,构建一个个性化的证候判别系统。基于HLYH大鼠模型的成功复制,我们通过整合体征、生化指标和代谢标志物,提取了该疾病的核心判别因素。将宏观和微观信息相关联以构建证候判别系统。在宏观层面,以血压升高为特征的HLYH大鼠模型被发现与水摄入量、痛阈、在旋转平台上的停留时间和体表温度的显著变化有关。共有27个潜在生物标志物和14条代谢途径似乎反映了主要的代谢特征。通过整合这些数据,我们成功构建了一个宏观-微观相结合的个性化证候判别系统,为HLYH风险位点的研究提供了基础。我们的发现也拓宽了我们对HLYH所涉及生物途径的理解。